Midodrine improves clinical and economic outcomes in patients with septic shock: a randomized controlled clinical trial.

Dina Hussein El AdlyNaglaa Samir BazanRadwa Maher El BorolossyIslam Fawzy AnanMohamed Amin FakherLamia Mohamed El Wakeel

Published in: Irish journal of medical science (2022)

The use of midodrine in septic shock patients significantly reduced IV norepinephrine duration, weaning period during the septic shock recovery phase, and mortality. Thus, the use of midodrine is dominant with less cost, better outcome and a cost-saving option in terms of budget impact analysis. This study was registered at clinicaltrials.gov (NCT 03,911,817) on April 11, 2019.

Keyphrases

septic shock
end stage renal disease
chronic kidney disease
ejection fraction
newly diagnosed
peritoneal dialysis
prognostic factors
risk factors
cardiovascular events
type diabetes
metabolic syndrome
coronary artery disease
patient reported outcomes
skeletal muscle
extracorporeal membrane oxygenation